CA3265173A1 - Il-36r antibodies for treatment of palmoplantar pustulosis - Google Patents

Il-36r antibodies for treatment of palmoplantar pustulosis

Info

Publication number
CA3265173A1
CA3265173A1 CA3265173A CA3265173A CA3265173A1 CA 3265173 A1 CA3265173 A1 CA 3265173A1 CA 3265173 A CA3265173 A CA 3265173A CA 3265173 A CA3265173 A CA 3265173A CA 3265173 A1 CA3265173 A1 CA 3265173A1
Authority
CA
Canada
Prior art keywords
antibodies
treatment
palmoplantar pustulosis
pustulosis
palmoplantar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3265173A
Other languages
English (en)
Inventor
Christian Thoma
Patrick BAUM
Janine LAMAR
Steven John PADULA
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA3265173A1 publication Critical patent/CA3265173A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3265173A 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis Pending CA3265173A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862785316P 2018-12-27 2018-12-27
US62/785,316 2018-12-27
US201962815431P 2019-03-08 2019-03-08
US62/815,431 2019-03-08
US201962891464P 2019-08-26 2019-08-26
US62/891,464 2019-08-26
CA3124996A CA3124996A1 (en) 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3124996A Division CA3124996A1 (en) 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis

Publications (1)

Publication Number Publication Date
CA3265173A1 true CA3265173A1 (en) 2025-10-31

Family

ID=69190739

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3265173A Pending CA3265173A1 (en) 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis
CA3124996A Pending CA3124996A1 (en) 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3124996A Pending CA3124996A1 (en) 2018-12-27 2019-12-20 Il-36r antibodies for treatment of palmoplantar pustulosis

Country Status (14)

Country Link
US (3) US20200207862A1 (enExample)
EP (1) EP3902604A1 (enExample)
JP (1) JP2022515480A (enExample)
KR (1) KR20210119407A (enExample)
CN (1) CN113301955A (enExample)
AU (1) AU2019416727A1 (enExample)
BR (1) BR112021010789A2 (enExample)
CA (2) CA3265173A1 (enExample)
CL (1) CL2021001685A1 (enExample)
IL (1) IL284259A (enExample)
MX (1) MX2021007807A (enExample)
PH (1) PH12021551540A1 (enExample)
TW (1) TW202037604A (enExample)
WO (1) WO2020136101A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
MX2023000763A (es) * 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
AU2021353854A1 (en) * 2020-09-30 2023-05-04 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
BR112023014103A2 (pt) * 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
MX2023012903A (es) * 2021-05-03 2023-11-08 Boehringer Ingelheim Int Metodo para producir spesolimab.
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2023285362A1 (en) * 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
EP4638492A2 (en) * 2022-12-23 2025-10-29 Icosavax, Inc. Antibodies against metapneumovirus fusion (f) protein and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
SI2780373T1 (sl) 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
US10526410B2 (en) * 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
US11690956B2 (en) 2015-04-24 2023-07-04 Shl Medical Ag Sub-assembly of a medicament delivery device and a medicament delivery device
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis

Also Published As

Publication number Publication date
EP3902604A1 (en) 2021-11-03
US20200207862A1 (en) 2020-07-02
US20230115617A1 (en) 2023-04-13
KR20210119407A (ko) 2021-10-05
CN113301955A (zh) 2021-08-24
MX2021007807A (es) 2021-08-11
BR112021010789A2 (pt) 2021-08-31
CL2021001685A1 (es) 2022-02-18
US20230131364A1 (en) 2023-04-27
PH12021551540A1 (en) 2022-02-21
AU2019416727A1 (en) 2021-07-22
TW202037604A (zh) 2020-10-16
CA3124996A1 (en) 2020-07-02
JP2022515480A (ja) 2022-02-18
WO2020136101A1 (en) 2020-07-02
IL284259A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
IL284259A (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
IL268479A (en) Anti-PD-1 antibodies for the treatment of lung cancer
EP3244926B8 (en) Treatment of cancer with anti-lap monoclonal antibodies
EP3402516A4 (en) USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
EP3880239A4 (en) THERAPEUTIC SIRPalpha ANTIBODIES
EP3110440A4 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
IL286000A (en) Asketamine for the treatment of depression
EP3227686A4 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
IL283948A (en) Methods for treating depression
IL282007A (en) Medicine to treat chronic cough
EP3110942A4 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
EP3289084A4 (en) siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER
EP3183002A4 (en) Monoclonal antibodies for treatment of microbial infections
EP3630754B8 (en) Isoindoline-acetylene compounds for the treatment of cancer
EP3999986A4 (en) ANTI-CLONING SYSTEM FOR INTERNET OF THINGS DEVICES
EP3873524B8 (en) Methods of treatment using anti-cd123 immunoconjugates
EP3755334A4 (en) TREATMENT OF LIVER DISEASES
EP3856784A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
EP3573634A4 (en) PREPARATION FOR WOUND TREATMENT
HK40062407A (en) Methods for the treatment of depression
HK40058314A (en) Use of anti-fam19a5 antibodies
HK40049516A (en) Kdm1a inhibitors for the treatment of disease
HK40018984A (en) Anti-pd-1 antibodies for treatment of lung cancer

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20250214

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250414

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250612

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250612

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250612

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250612

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250613

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250613

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250627

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250630

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250630

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250709

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20251031

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251212

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260723